104 related articles for article (PubMed ID: 11173931)
1. Erythropoietin in urologic oncology.
Albers P; Heicappell R; Schwaibold H; Wolff J;
Eur Urol; 2001 Jan; 39(1):1-8. PubMed ID: 11173931
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin in the management of patients with nonhematologic cancer receiving chemotherapy. Systemic Treatment Program Committee.
Quirt I; Micucci S; Moran LA; Pater J; Browman G
Cancer Prev Control; 1997 Aug; 1(3):241-8. PubMed ID: 9765749
[TBL] [Abstract][Full Text] [Related]
3. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?].
Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F
Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
[TBL] [Abstract][Full Text] [Related]
5. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
6. EPO in cancer anemia: benefits and potential risks.
Milano M; Schneider M
Crit Rev Oncol Hematol; 2007 May; 62(2):119-25. PubMed ID: 17197190
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human erythropoietin β: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients.
Durmaz O; Demirkaya M; Sevinir B
Pediatr Hematol Oncol; 2011 Sep; 28(6):461-8. PubMed ID: 21707225
[TBL] [Abstract][Full Text] [Related]
8. The blue cross blue shield assessment technology review: summary of findings.
Bennett CL
Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
[TBL] [Abstract][Full Text] [Related]
9. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
[TBL] [Abstract][Full Text] [Related]
10. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure.
Nemoto T; Yokota N; Keane WF; Rabb H
Kidney Int; 2001 Jan; 59(1):246-51. PubMed ID: 11135077
[TBL] [Abstract][Full Text] [Related]
11. Financial impact of the introduction of erythropoietin in the treatment of anemia of premature infants in Israel.
Dollberg S; Mimouni FB
Isr Med Assoc J; 1999 Oct; 1(2):86-8. PubMed ID: 10731302
[TBL] [Abstract][Full Text] [Related]
12. Treating anemia associated with chronic renal failure with erythropoiesis stimulators: recombinant human erythropoietin might be the best among the available choices.
Trkulja V
Med Hypotheses; 2012 Jan; 78(1):157-61. PubMed ID: 22078846
[TBL] [Abstract][Full Text] [Related]
13. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer.
de Campos E; Radford J; Steward W; Milroy R; Dougal M; Swindell R; Testa N; Thatcher N
J Clin Oncol; 1995 Jul; 13(7):1623-31. PubMed ID: 7602351
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin, uncertainty principle and cancer related anaemia.
Clark O; Adams JR; Bennett CL; Djulbegovic B
BMC Cancer; 2002 Sep; 2():23. PubMed ID: 12270068
[TBL] [Abstract][Full Text] [Related]
15. [The role of human recombinant erythropoietin in oncologic surgery].
Mercuriali F
Tumori; 1997; 83(4 Suppl 2):S16-9. PubMed ID: 9487379
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S; McCormick B
J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
[TBL] [Abstract][Full Text] [Related]
17. Comparison of a restricted transfusion schedule with erythropoietin therapy versus a restricted transfusion schedule alone in very low birth weight premature infants.
Birenbaum HJ; Pane MA; Helou SM; Starr KP
South Med J; 2006 Oct; 99(10):1059-62. PubMed ID: 17100024
[TBL] [Abstract][Full Text] [Related]
18. Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care.
Lönnroth C; Svensson M; Wang W; Körner U; Daneryd P; Nilsson O; Lundholm K
Med Oncol; 2008; 25(1):22-9. PubMed ID: 18188711
[TBL] [Abstract][Full Text] [Related]
19. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
Fujita Y; Inoue S; Horiguchi S; Kuki A
Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
[TBL] [Abstract][Full Text] [Related]
20. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
Spaepen E; Demarteau N; Van Belle S; Annemans L
Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
